COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special called meeting will be held virtually via Zoom webinar.
Thursday, May 19, 2022
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

<table>
<thead>
<tr>
<th>Smartphone/Web</th>
<th>Dial-In</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://magellanhealth.zoom.us/s/93101597504">https://magellanhealth.zoom.us/s/93101597504</a></td>
<td>+1 312 626 6799 (US Toll) OR</td>
</tr>
<tr>
<td>Webinar ID: 931 0159 7504</td>
<td>+1 646 558 8656 (US Toll)</td>
</tr>
<tr>
<td>Password: 981071</td>
<td>Webinar ID: 931 0159 7504</td>
</tr>
<tr>
<td></td>
<td>Passcode: 981071</td>
</tr>
</tbody>
</table>

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
   a. Approval of March 2022 Meeting Minutes

IV. New Business
   a. New Products to Market to be reviewed as single products:
      i. Cibinqo™ (Cytokine and CAM Antagonists)
      ii. Adbry™ (Immunomodulators, Atopic Dermatitis)
      iii. Tavneos™ (Immunosuppressants)
      iv. Leqvio® (Lipotropics: Other)
      v. Vyvgart™ (Immunomodulators, miscellaneous)
      vi. Besemri™ (Immunomodulators, miscellaneous)
      vii. Tezspire™ (Immunomodulators, Asthma)

I. New Therapeutic Classes
   a. Immunomodulators, Asthma
   b. Uterine Disorder Treatments

II. Therapeutic Classes with Recommended Changes
   a. Analgesics, Narcotics Short
   b. Analgesics, Narcotics Long Acting
   c. Antihyperuricemics
   d. Antimigraine Agents, Other (Antimigraine Agents, CGRP Inhibitors)
   e. Bone Resorption Suppression & Related Agents
   f. Colony Stimulating Factors
   g. Glucagon Agents
   h. Glucocorticoids, Oral
   i. Hypoglycemics, Incretin Mimetics/Enhancers (Diabetes: DPP4 Inhibitors)
   j. Hypoglycemics, Insulins & Related
k. Phosphate Binders

V. Consent Agenda
   a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<table>
<thead>
<tr>
<th>Androgenic Agents</th>
<th>Hypoglycemics, Thiazolidinediones (TZD) (Diabetes: Thiazolidinediones)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimigraine Agents – Triptans (Antimigraine Agents - 5-HT1Receptor Agonists)</td>
<td>Narcotics: Agonist/Antagonists</td>
</tr>
<tr>
<td>Erythropoiesis Stimulating Proteins</td>
<td>Narcotics: Fentanyl Buccal Products</td>
</tr>
<tr>
<td>Growth Hormone</td>
<td>Neuropathic Pain</td>
</tr>
<tr>
<td>Hypoglycemics, Alphaglucosidase inhibitors (Diabetes: AlphaGlucosidase Inhibitors)</td>
<td>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</td>
</tr>
<tr>
<td>Hypoglycemics, Incretin Mimetics/Enhancers (Diabetes: GLP-1 Agonists)Hypoglycemics, Meglitinides (Diabetes: Meglitinides)</td>
<td>Opiate Dependence Treatments</td>
</tr>
<tr>
<td>Hypoglycemics, Metformins (Diabetes: Metformins)</td>
<td>Pancreatic Enzymes</td>
</tr>
<tr>
<td>Hypoglycemics, SGLT2 Inhibitors (Diabetes: SGLT2 Inhibitors)</td>
<td>Progestins for Cachexia</td>
</tr>
<tr>
<td>Hypoglycemics, Sulfonylureas (Diabetes: Sulfonylureas)</td>
<td>Skeletal Muscle Relaxants</td>
</tr>
<tr>
<td></td>
<td>Thrombopoiesis Stimulating Proteins (Thrombopoiesis Stimulating Agents)</td>
</tr>
</tbody>
</table>

V. Adjournment
   a. Schedule of Upcoming Meetings
      i. July 21, 2022
      ii. September 15, 2022

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to [https://kyportal.magellanmedicaid.com/provider/public/home.xhtml](https://kyportal.magellanmedicaid.com/provider/public/home.xhtml).

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: [https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml](https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml).